Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.

被引：0
|
作者：
Sharma, Padmanee
Krainer, Michael
Saad, Fred
Castellano, Daniel
Bedke, Jens
Kwiatkowski, Mariusz
Patnaik, Akash
Procopio, Giuseppe
Wiechno, Pawel
Kochuparambil, Samith Thomas
Thomas, Christian
Arija, Jose Angel Arranz
McCune, Steven L.
Hansen, Steinbjorn
Daugaard, Gedske
Amin, Neha P.
Wang, Yumeng
David, Justin M.
Pachynski, Russell Kent
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Montreal Hosp Ctr, Montreal, PQ, Canada
[4] Hosp Univ 12 Octubre, Madrid, Spain
[5] Eberhard Karls Univ Tubingen, Tubingen, Germany
[6] Szpital Wojewodzki Mikolaja Kopernika w Koszalini, Oddzial Dzienny Chemioterapii, Koszalin, Poland
[7] Univ Chicago Med, Chicago, IL USA
[8] Ist Nazl Tumori Milano, Milan, Italy
[9] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[10] Minnesota Oncol, Minneapolis, MN USA
[11] Natl Ctr Tumor Dis, Heidelberg, Germany
[12] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[13] Northwest Georgia Oncol Ctr, Marietta, GA USA
[14] Odense Univ Hosp, Odense, Denmark
[15] Rigshosp, Univ Copenhagen Hosp, Copenhagen, Denmark
[16] Bristol Myers Squibb, Princeton, NJ USA
[17] Washington Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study).
    Fleisher, Martin
    Danila, Daniel Costin
    Fizazi, Karim
    Hirmand, Mohammad
    Selby, Brian
    Phung, De
    De Bono, Johann Sebastian
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
    Mark C. Markowski
    Mary-Ellen Taplin
    Rahul Aggarwal
    Laura A. Sena
    Hao Wang
    Hanfei Qi
    Aliya Lalji
    Victoria Sinibaldi
    Michael A. Carducci
    Channing J. Paller
    Catherine H. Marshall
    Mario A. Eisenberger
    David E. Sanin
    Srinivasan Yegnasubramanian
    Carolina Gomes-Alexandre
    Busra Ozbek
    Tracy Jones
    Angelo M. De Marzo
    Samuel R. Denmeade
    Emmanuel S. Antonarakis
    Nature Communications, 15
  • [33] Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
    Markowski, Mark C.
    Taplin, Mary-Ellen
    Aggarwal, Rahul
    Sena, Laura A.
    Wang, Hao
    Qi, Hanfei
    Lalji, Aliya
    Sinibaldi, Victoria
    Carducci, Michael A.
    Paller, Channing J.
    Marshall, Catherine H.
    Eisenberger, Mario A.
    Sanin, David E.
    Yegnasubramanian, Srinivasan
    Gomes-Alexandre, Carolina
    Ozbek, Busra
    Jones, Tracy
    De Marzo, Angelo M.
    Denmeade, Samuel R.
    Antonarakis, Emmanuel S.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [34] A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates
    Coyne, Geraldine O'Sullivan
    Jochems, Caroline
    Heery, Christopher
    Singh, Harpreet
    Surolia, Ira
    Riley, Robin
    Madan, Ravi
    Dahut, William
    Steinberg, Seth
    Gulley, James
    Schlom, Jeffrey
    CANCER RESEARCH, 2014, 74 (19)
  • [35] A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
    Jochems, Caroline
    Tucker, Jo A.
    Tsang, Kwong-Yok
    Madan, Ravi A.
    Dahut, William L.
    Liewehr, David J.
    Steinberg, Seth M.
    Gulley, James L.
    Schlom, Jeffrey
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (04) : 407 - 418
  • [36] A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)
    Chen, Yu-Wei
    Liu, Lin
    Pu, Minya
    Pena, Samuel
    Qin, Qian
    Zhang, Tian
    Emamekhoo, Hamid
    Lang, Joshua Michael
    Patnaik, Akash
    McKkay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS239 - TPS239
  • [37] A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.
    Antonarakis, E. S.
    Heath, E. I.
    Smith, D. C.
    Rathkopf, D. E.
    Blackford, A. L.
    Danila, D. C.
    King, S.
    Frost, A.
    Carducci, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [39] Phase III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC): A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - AUO Study AP 118/21
    Rexer, Heidrun
    Boegemann, Martin
    Hammerer, Peter
    AKTUELLE UROLOGIE, 2022, 53 (03) : 226 - 228
  • [40] Everolimus plus bicalutamide in men with castration-resistant prostate cancer (CRPC): Final results of a phase II trial.
    Pan, Chong-xian
    Chow, Helen
    Ghosh, Paramita
    White, Ralph deVere
    Evans, Christopher P.
    Dall'Era, Marc A.
    Yap, Stanley A.
    Li, Judy
    Beckett, Laurel A.
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345